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A B S T R A C T
Objective: To assess the convergent and discriminative validity of the Health Utilities Index
Mark 3 (HUI-3) for patients with ankylosing spondylitis (AS).
Methods: DatawerederivedfromtheAdalimumabTrialevaluatingLong-termefficacyandsafety
for Ankylosing Spondylitis (ATLAS). The study team specified 90 a priori hypotheses regarding the
direction and magnitude of the expected associations between the overall and single-attribute
scores of the HUI-3 and other health status and quality-of-life measures: Short Form 36 Health
Survey (SF-36), Ankylosing Spondylitis Quality-of-Life Questionnaire, Bath Ankylosing Spondylitis
Functional Index, BathAnkylosing Spondylitis DiseaseActivity Index, BathAnkylosing Spondylitis
Metrology Index, and Patient’s and Physician’s Global Assessments of DiseaseActivity.With base-
line data, correlation coefficients were calculated and interpreted according to the guidelines sug-
gested by Guyatt for negligible (0–0.19), weak (0.20–0.34), moderate (0.35–0.50), and strong (0.5)
associations. The a priori hypotheseswere tested using Pearson’s correlation coefficients.
Results: A total of 315 patients with active ASwere randomized and enrolled in ATLAS. The
correlation coefficients between the HUI-3 scores and other health-related quality-of-life
instruments confirmed 61.1% of the a priori hypotheses, with an additional 35.5% being
under- or overestimated by one correlation category.
Conclusion: These results provide evidence of the cross-sectional, convergent, and dis-
criminative validity of the HUI-3 for deriving utility scores in patients with AS.
Copyright © 2011, International Society for Pharmacoeconomics and Outcomes Research
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161V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 6 0 – 1 6 5ntroduction
nkylosing spondylitis (AS) is a chronic, inflammatory, rheu-
atic disease with onset typically between 20 to 40 years of
ge. The disease affects the axial skeleton, large peripheral
oints, and entheses. Disease progression results in pain, joint
tiffness, and varying degrees of spinal fusion, which can im-
act patients’ health-related quality of life (HRQoL) consider-
bly. The burden of AS can be substantial to patients, their
amilies, and society [1]. AS leads to functional limitations,
nd poor physical function is the major predictor of high di-
ect and productivity costs, including cost of disease-related
ork disability [2]. Health-care costs related to medication
nd health-care provider expenses are substantial [1]. Pre-
enting disease progression is of great importance in mini-
izing the impact of AS [3].
Increasing demands for health-care treatments and ser-
ices, coupled with limited health-care resources, have re-
ulted in decision makers requiring information pertaining to
he relative cost effectiveness of medical interventions. As-
essing cost effectiveness requires ameasure of the benefit an
ntervention provides to patients. StandardizedHRQoL instru-
ents have been developed to assess the burden and to mea-
ure effectiveness of health-care interventions for specific dis-
ases. Quality-adjusted life-years (QALYs), which are derived
rom patient utility measurements, are also used and are fre-
uently considered the gold standard for comparing the effec-
iveness of different medical interventions [4]. The Health
tilities Index Mark 3 (HUI-3) is a comprehensive, preference-
ased, self-reported measure of health status that covers
ight attributes of functional ability. The HUI-3 provides a
ummary of health utility scores that can be used to estimate
ALYs when the time period spent in the HUI-3 level is in-
luded in the calculation [5]. We sought to determine the con-
truct validity of the HUI-3 for patients with AS by examining
ts relationship with other validated AS-specific and generic
RQoL instruments.
ethods
ata source
ata were derived from the Adalimumab Trial evaluating
ong-term efficacy and safety for Ankylosing Spondylitis
ATLAS), a phase III, placebo-controlled, double-blind, ran-
omized, multicenter study conducted at 43 sites in the
nited States and Europe (ClinicalTrials.gov identifier:
CT00085644) [6]. This trial assessed the safety and efficacy of
dalimumab in the treatment of 315 patients with active AS
ho had an inadequate response or intolerance to one or
ore nonsteroidal anti-inflammatory drugs and who addi-
ionally may have failed one or more disease-modifying anti-
heumatic drugs. The study was conducted in accordance
ith the International Conference on Harmonisation guide-
ines and the Declaration of Helsinki. Informed consent was
btained from each patient and each participating site re-
eived ethics approval. Only baseline data were used for this tnalysis. The full study methodology and results have been
ublished in detail [6–10].
tudy population and study design
atients were adults at least 18 years of agewith a diagnosis of
S according to modified New York criteria [11]. Patients also
ulfilled at least two of the following three criteria: Bath Anky-
osing Spondylitis DiseaseActivity Index (BASDAI) score of4,
otal back pain score of 40 (visual analogue scale [VAS] of
–100 mm), or duration of morning stiffness 1 hour.
ealth status and HRQoL measures
nkylosing Spondylitis Quality-of-Life Questionnaire (ASQoL)
he ASQoL is a self-administered assessment to evaluate the
uality of life in patients with AS [12,13]. The ASQoL consists
f 18 questions (yes or no responses) related to the impact of
S pain on the following eight aspects: patient’s ability to
ope, relationships, mood, sleep, motivation, activities of ev-
ryday living, independence, and social life. The score is mea-
ured numerically on a scale of 0 to 18, with 0 representing the
est quality of life and 18 representing the worst [12,13].
ASDAI
he BASDAI is a self-administered questionnaire that as-
esses the disease activity level of AS [14]. The BASDAI con-
ists of six, 10-cm, horizontal VAS questions to measure se-
erity of the five major symptoms of AS: fatigue, spinal and
eripheral joint pain, localized tenderness, andmorning stiff-
ess [14]. The BASDAI is reported on a scale of 0 to 10, and
igher BASDAI scores indicate greater AS disease activity.
ath Ankylosing Spondylitis Functional Index (BASFI)
he BASFI is a disease-specific index that assesses physical
unctional impairment due to AS [15]. The greater the BASFI
core, the greater the severity of the patient’s functional lim-
tations.
ath Ankylosing Spondylitis Metrology Index (BASMI)
he BASMI is a composite index of five clinical measurements
f spinal mobility in AS. These measurements include evalu-
tions of cervical rotation, tragus to wall distance, lateral flex-
on, lumbar flexion (modified Schober test), and intermalleolar
istance [16].
UI-3
he HUI-3 is a preference-basedmeasure of health status that
an be used to determine utility scores [17,18]. Patients are
sked to recall specific health-related aspects of their experi-
nce over the past 4-week period. The HUI-3 system used in
he study includes a health classification system and a for-
ula for calculating scores to evaluate the comprehensive
tate of an individual’s health status. HUI-3 consists of five or
ix levels for each of eight attributes (vision, hearing, speech,
mbulation, dexterity, cognition, emotion, and pain) [17,19].
evels within each attribute range from no problem or normal
free of pain and discomfort) to severe disability (severe pain
hat prevents most activities). Single-attribute HUI-3 utility
s
a
f
r
v
s
r
P
P
T
b
(
(
p
V
T
m
p
[
S
T
t
e
d
p
t
m
C
m
i
S
P
t
t
a
H
P
[
v
t
b
d
s
a
A
(
t
T
r
d
w
m
c
0
c

s
d
s
a
s
r
w
m
a
w
b
c
w
t
t
d
c
t
c
T
w
p
t
A
a
u
B
w
s
p
S
r
P
s
n
(
i
t
R
P
A
A
a
l
r
162 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 6 0 – 1 6 5cores are reported on a scale in which no problem or no dis-
bility is scored as 1.00 and the most severe level of disability
or a given attribute is scored as 0.0. Overall HUI-3 scores are
eported on a dead to healthy scale and may have negative
alues (range, –0.36 to 1.00); negative values indicate a health
tatus worse than dead. The overall HUI-3 utility scores are
eported with a maximum value of 1.00 [20].
atient’s and Physician’s Global Assessments (PaGA and
hGA) of Disease Activity
he degree of disease activity was evaluated using a VAS for
oth the PaGA and the PhGA. The left anchor of the VAS
0mm) indicated absence of symptoms and the right anchor
100 mm) indicated very high disease activity. The recall
eriod for both the PaGA and the PhGA was 1 week.
AS pain
otal back pain and nocturnal pain were two attributes also
easured by a VAS. Both attributes had a recall period of
ain experienced over the past week prior to the evaluation
21].
hort Form 36 Health Survey (SF-36)
he SF-36 is a generic, 36-question health survey used to de-
ermine health status [22]. Patients are to recall their experi-
nces over the past 4-week period. The SF-36 consists of eight
omain profiles: physical functioning, role–physical, bodily
ain, general health, vitality, social functioning, role–emo-
ional, and mental health. The SF-36 then combines the do-
ain profiles to provide two summary scores: the Physical
omponent Summary (PCS) and the Mental Component Sum-
ary (MCS). The score is transformed to a 0 to 100-point scale,
n which greater scores represent better HRQoL.
tatistical analysis
rior to conducting the analyses, a subcommittee of the au-
hors formulated a total of 90 a priori hypotheses concerning
he magnitude of association expected between the overall
nd single-attribute HUI-3 scores and other health-status and
RQoL measures, including: SF-36, ASQoL, BASFI, BASDAI,
aGA, and PhGA. This strategy has been published previously
23] and enhances the interpretation of results regarding con-
ergent and discriminative validity. Convergent validity refers
o whether measures of constructs that theoretically should
e related to each another are observed to be related, whereas
iscriminative validity refers to whether measures of con-
tructs that theoretically should not be related to each another
re observed to be unrelated.
The subcommittee included three rheumatologists (R.W.,
.P., D.V.), a psychometrician (D.R.), and a health economist
D.F.). The subcommittee arrived at the a priori hypotheses
hrough a nonbiased, iterative, consensus-building process.
he subcommittee members first established the a priori cor-
elations independently, and consensus meetings were un-
ertaken to resolve any discrepancies. The a priori hypotheses
ere formulated using criteria for the interpretation of the
agnitude of correlations suggested by Guyatt et al. [24]. The
riteria suggest that a negligible correlation ranges from 0.0 to s.19, a weak correlation ranges from 0.20 to 0.34, a moderate
orrelation ranges from 0.35 to 0.50, and a strong correlation is
0.50.
For single-attribute HUI-3 scores that were not typical
ymptoms of AS, weak to negligible correlations were pre-
icted for all patient-reported outcomes (PROs). For hearing,
peech, and cognition, it was hypothesized that these single-
ttribute HUI-3 scores would have negligible correlations with
cores from all of the other quality-of-life assessments. With
espect to HUI-3 dexterity scores, we hypothesized that they
ould have weak correlations with scores from the following
easures: BASFI, BASDAI, BASMI, SF-36 PCS, ASQoL, PaGA,
nd PhGA. We also hypothesized that HUI-3 dexterity scores
ould have negligible correlations with nocturnal pain, total
ack pain, and SF-36 MCS scores.
For the HUI-3 emotion scores, we anticipated that strong
orrelationswith SF-36MCS scores andmoderate correlations
ith ASQoL scores would be observed. Weak correlations be-
ween the HUI-3 emotions attribute and BASFI, BASDAI, noc-
urnal pain, total back pain, SF-36 PCS, and PaGA were pre-
icted. HUI-3 emotion scoreswere predicted to have negligible
orrelations with the BASMI and PhGA.
Many of the PROs used in the assessment of AS address
he burdens of pain and function, which are the primary
auses for consultation and treatment in patients with AS.
herefore, we expected single-attribute HUI-3 pain scores
ould have strong correlations with scores for nocturnal
ain, total back pain, and the PaGA and moderate correla-
ions with scores for BASFI, BASDAI, BASMI, SF-36 PCS, and
SQoL. A weak correlation was hypothesized for HUI-3 pain
nd SF-36 MCS. For the ambulation single-attribute HUI-3
tility scores, moderate correlations with scores from
ASFI, BASDAI, BASMI, total back pain, SF-36 PCS, and PaGA
ere hypothesized. Weak correlations between ambulation
cores and scores for nocturnal pain, ASQoL, and PhGAwere
redicted. A negligible correlation for HUI-3 ambulation and
F-36 MCS scores was expected.
Overall HUI-3 scores were predicted to have moderate cor-
elations with scores from BASFI, BASDAI, SF-36 PCS, ASQoL,
aGA, and PhGA. We also hypothesized that overall HUI-3
cores would have weak correlations with scores from BASMI,
octurnal pain, total back pain, and SF-36 MCS.
To test the a priori hypotheses, zero-order correlations
two-tailed) were conducted for the various scales. The signif-
cance level was set to 0.05. The a priori hypotheses were
ested using Pearson’s correlation coefficients.
esults
atient entry and baseline characteristics
total of 315 patients were randomized and enrolled in the
TLAS study. The mean age was 42 years, 74.9% were men,
nd the average duration of AS was 10.9 years (Table 1). Base-
ine scores for the various HRQoL assessments are summa-
ized in Table 2. The overall and single-attribute pain HUI-3
cores indicated severe disability at baseline (Table 3).
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163V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 6 0 – 1 6 5ssessment of a priori hypotheses
verall, 55 (61%) of the 90 a priori hypotheses were supported.
he results of the zero-order correlations (two-tailed) of the
ingle-attribute (ambulation and pain) and overall utility
cores of the HUI-3 and the various health status and HRQoL
nstruments (ASQoL, BASDAI, BASFI, PaGA, and PhGA and
F-36 MCS and PCS) are presented in Tables 4 to 6. For the
verall HUI-3 score results (Table 4), the predicted correlations
or instruments that are specific to physical function and AS
isease activity were all matched to the observed data. As
redicted, moderate correlations between the overall HUI-3
nd BASDAI, BASFI, and SF-36 PCS scores were observed.
trong correlations between the overall HUI-3 and the ASQoL
nd PaGA scores were observed. However, moderate correla-
ions were originally predicted for these measures.
For the single-attribute scores, 30% of the a priori predic-
Table 1 – Demographic and clinical characteristics of the
ATLAS cohort at baseline.
ATLAS cohort
(N  315)
Age (years), mean (range) 42 (18–71)
Male, n (%) 236 (74.9)
White, n (%) 301 (95.6)
Duration of AS (years), mean (SD) 10.9 (9.5)
AS, ankylosing spondylitis; ATLAS, Adalimumab Trial evaluating
Long-term efficacy and safety for Ankylosing Spondylitis; SD, stan-
dard deviation.
Table 2 – Baseline disease status and HRQoL scores.
Disease status or
HRQoL measure
Range N* Baseline,
mean
(SD)
BASFI 0–10† 315 5.4 (2.2)
BASDAI 0–10† 315 6.3 (1.7)
BASMI 0–10† 315 3.9 (2.2)
Nocturnal pain VAS, 0–100 mm† 314 61.9 (23.8)
Total back pain VAS, 0–100 mm† 315 65.3 (21.1)
SF-36 PCS 0–100‡ 311 32.5 (8)
SF-36 MCS 0–100‡ 311 43.7 (11.6)
ASQoL 0–18† 315 10.3 (4.3)
PaGA VAS, 0–100 mm† 314 63.4 (21.1)
PhGA VAS, 0–100 mm† 314 57.2 (18.7)
ASQoL, Ankylosing Spondylitis Quality-of-Life Questionnaire;
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI,
Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Anky-
losing Spondylitis Metrology Index; HRQoL, health-related quality
of life; MCS, Mental Component Summary; PaGA, Patient’s Global
Assessment of Disease Activity; PCS, Physical Component Sum-
mary; PhGA, Physician’s Global Assessment of Disease Activity; SD,
standard deviation; SF-36, Short Form 36Health Survey; VAS, visual
analog scale.
* Sample-size changes with type of HRQoL assessment because
some patients had missing responses and their scores could not
be computed.
† Greater values indicate worse status.
‡ Greater values indicate better status.ions were matched for ambulation (Table 5) and 50% were
atched for pain (Table 6). These results support convergent
alidity of the HUI-3 in patients with AS. The a priori correla-
ion hypotheses of the HUI-3 single-attribute scores not re-
ated to instruments that measure the clinical symptoms as-
ociated with AS were matched at 100% for hearing, 100% for
peech, 70% for dexterity, 70% for vision, 60% for cognition,
nd 40% for emotion. These results support the discriminative
alidity of HUI-3 in patients with AS.
iscussion
verall, 61% of our 90 a priori hypotheses concerning the re-
ationship between HUI-3 utility scores (single-attribute and
verall) and known, validated health status and HRQoL mea-
Table 3 – Baseline overall and single-attribute HUI-3
scores.
HUI-3
attribute
Baseline, mean (SD)
(N315)
Interpretation
Overall 0.48 (0.26) Severe disability
Vision 0.94 (0.13) Mild disability
Hearing 0.96 (0.15) Mild disability
Speech 0.99 (0.06) No disability
Ambulation 0.90 (0.12) Mild disability
Dexterity 0.95 (0.13) Mild disability
Emotion 0.85 (0.19) Mild to moderate disability
Cognition 0.87 (0.2) Mild disability
Pain 0.54 (0.25) Severe disability
HUI-3, Health Utilities Index Mark 3; SD, standard deviation.
Table 4 – Comparison of a priori and observed
correlations for overall HUI-3 scores.
Disease status or
HRQoL measure
A priori
hypothesis
Correlation
coefficient*
Observed
correlation†
BASFI Moderate –0.48 Moderate‡
BASDAI Moderate –0.42 Moderate‡
BASMI Weak –0.16 Negligible
Nocturnal pain Weak –0.42 Moderate
Total back pain Weak –0.42 Moderate
SF-36 PCS Moderate 0.44 Moderate‡
SF-36 MCS Weak 0.49 Moderate
ASQoL Moderate –0.70 Strong
PaGA Moderate –0.53 Strong
PhGA Moderate –0.29* Weak
ASQoL, Ankylosing Spondylitis Quality-of-Life Questionnaire;
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI,
Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Anky-
losing Spondylitis Metrology Index; HRQoL, health-related quality
of life; HUI-3, Health Utilities Index Mark 3; MCS, Mental Compo-
nent Summary; PaGA, Patient’s Global Assessment of Disease Ac-
tivity; PCS, Physical Component Summary; PhGA, Physician’s
Global Assessment of Disease Activity; SF-36, Short Form 36 Health
Survey.
* All correlation coefficients significant at P  0.001.
† Correlation categories: negligible 0.00–0.19, weak 0.20–0.34,
moderate 0.35–0.50, and strong 0.50.
‡ The a priori hypothesis was supported.
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164 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 6 0 – 1 6 5ures were confirmed, supporting the potential use of the
UI-3 in patients with AS. Convergent validity was demon-
trated, as certain disease-specific or pain- and function-re-
ated PROs were correlated with the overall HUI-3 score, as
ell as the pain and ambulation single-attribute HUI-3 scores.
Of note, sample size has a strong impact on the P value of
he statistical test of a correlation; therefore, correlation coef-
cientswere calculated andwe classified all correlations as neg-
igible, weak, moderate, or strong according to Guyatt et al. [24].
Although the overall percentage of a priori hypotheses that
ere confirmed is acceptable, 39% of our a priori hypotheses
ere not confirmed. In examining zero-order correlations, the
ajority of our unconfirmed a priori hypotheses related to
verall HUI-3 and single-attribute ambulation scores. Notably,
hese a priori correlations weremostly estimated as convergent
t a lower strength as actually calculated. In particular, our re-
ults partly demonstrated better convergent validity than ex-
ected for correlations of the overall HUI-3 with nocturnal pain,
otal back pain, SF-36 MCS, ASQoL, and PaGA and of the single-
ttribute ambulation with ASQoL. Discriminative validity was
lso demonstrated, whereby the single-attribute HUI-3 scores
hat are not symptoms of AS (eg, dexterity) were not correlated
ith the disease-specific or pain- and function-related PROs.
The degree of agreement between predicted and observed
orrelations in studies with similar methodology ranged from
0% to 75%; thus, our success rate is consistent with previous
esearch. For example, in a study of patients undergoing elec-
ive total hip arthroplasty, Blanchard et al. [23] reported a suc-
ess rate of 75%. In two studies involving children with
sthma [25,26] and a study of high-risk primary-care patients
Table 5 – Comparison of a priori and observed
correlations for ambulation single-attribute HUI-3 score.
Disease status
or HRQoL
measure
A priori
hypothesis
Correlation
coefficient*
Strength of
observed
correlation†
BASFI Moderate –0.40 Moderate‡
BASDAI Moderate –0.20 Weak
BASMI Moderate –0.22 Weak
Nocturnal pain Weak –0.11 Negligible
Total back pain Moderate –0.14 Negligible
SF-36 PCS Moderate 0.40 Moderate‡
SF-36 MCS Negligible 0.13 Negligible‡
ASQoL Weak –0.36 Moderate
PaGA Moderate –0.23 Weak
PhGA Weak –0.19 Negligible
ASQoL, Ankylosing Spondylitis Quality-of-Life Questionnaire;
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI,
Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Anky-
losing Spondylitis Metrology Index; HRQoL, health-related quality
of life; HUI-3, Health Utilities Index Mark 3; MCS, Mental Compo-
nent Summary; PaGA, Patient’s Global Assessment of Disease Ac-
tivity; PCS, Physical Component Summary; PhGA, Physician’s
Global Assessment of Disease Activity; SF-36, Short Form 36 Health
Survey.
* All correlation coefficients significant at P  0.001.
† Correlation categories: negligible 0.00–0.19, weak 0.20–0.34,
moderate 0.35–0.50, and strong 0.50.
‡d
The a priori hypothesis was supported.27], success rates of 50% were reported. Likewise, Feeny et al.
28] reported a success rate of 58% in a study using data from a
opulation health survey.
The study has notable strengths. First, the study sample
ize was adequate to show validity in comparison with the
ther HRQoL instruments. Second, a priori predictions were
ade regarding the direction of relationship and magnitude
f association between the measures. Third, the application
nd results of this study conform to parts of the Outcome
easures in Rheumatology (OMERACT) filter, whereby the
UI-3 demonstrates truth and discrimination [29]. A limita-
ion of the study is that a BASDAI score 4 was an inclusion
riterion for ATLAS; therefore, it is unknown whether these
esults are generalizable to patients with less severe AS.
onclusion
his study provides evidence of the convergent and discrimi-
ative validity of the HUI-3 for deriving utility scores in pa-
ients with AS. On the basis of such evidence of overall con-
truct validity, these results suggest that the HUI-3 is an
ppropriate measurement tool for assessment of HRQoL and
tility in patients with AS.
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